Ansell SM, et al. - In this phase II, open-label study, researchers investigated the efficacy and safety of programmed death-1 blockade by nivolumab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced failure with auto-HCT. Findings revealed a favorable safety profile of nivolumab monotherapy but with a low overall response rate in these patients. In DLBCL, infrequent genetic alterations of 9p24.1 were noted.